Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cerilliant
Queensland Health
Cipla
Citi
UBS
US Department of Justice
Daiichi Sankyo
Fuji
Cantor Fitzgerald

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,642,025

« Back to Dashboard

Which drugs does patent 8,642,025 protect, and when does it expire?

Patent 8,642,025 protects DAKLINZA and is included in one NDA.

This patent has forty-seven patent family members in thirty-one countries.
Summary for Patent: 8,642,025
Title:Hepatitis C virus inhibitors
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s): Bachand; Carol (Candiac, CA), Belema; Makonen (North Haven, CT), Deon; Daniel H. (Montreal, CA), Good; Andrew C. (Wallingford, CT), Goodrich; Jason (Wallingford, CT), James; Clint A. (Candiac, CA), Lavoie; Rico (Candiac, CA), Lopez; Omar D. (Wallingford, CT), Martel; Alain (Delson, CA), Meanwell; Nicholas A. (East Hampton, CT), Nguyen; Van N. (Middletown, CT), Romine; Jeffrey Lee (Meriden, CT), Ruediger; Edward H. (Greenfield Park, CA), Snyder; Lawrence B. (Killingworth, CT), St. Laurent; Denis R. (Newington, CT), Yang; Fukang (Madison, CT), Langley; David R. (Meriden, CT), Hamann; Lawrence G. (North Grafton, MA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:13/650,374
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,642,025

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y METHOD OF INHIBITING HEPATITIS C VIRUS ➤ Subscribe
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y Y METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY ➤ Subscribe
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-002 Jul 24, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y METHOD OF INHIBITING HEPATITIS C VIRUS ➤ Subscribe
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-002 Jul 24, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,642,025

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,900,566 Hepatitis C virus inhibitors ➤ Subscribe
8,303,944 Hepatitis C virus inhibitors ➤ Subscribe
9,758,487 Hepatitis C virus inhibitors ➤ Subscribe
8,329,159 Hepatitis C virus inhibitors ➤ Subscribe
9,227,961 Hepatitis C virus inhibitors ➤ Subscribe
8,846,023 Hepatitis C virus inhibitors ➤ Subscribe
8,574,563 Hepatitis C virus inhibitors ➤ Subscribe
9,421,192 Hepatitis C virus inhibitors ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,642,025

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I432426 ➤ Subscribe
Taiwan 200813029 ➤ Subscribe
Taiwan I400072 ➤ Subscribe
Taiwan 200934486 ➤ Subscribe
Slovenia 2784075 ➤ Subscribe
Slovenia 2049522 ➤ Subscribe
Portugal 2049522 ➤ Subscribe
Poland 2784075 ➤ Subscribe
Peru 05422008 ➤ Subscribe
New Zealand 574805 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Express Scripts
Accenture
Citi
Farmers Insurance
McKesson
QuintilesIMS
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot